Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors

NCT ID NCT07680257

Disease control Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that have not responded to standard treatments. Researchers are primarily looking at safety and the right dose, while also checking how long the cells last in the body and whether they have any effect on the tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SUV2208A (CLDN18.2-targeted CAR T cells)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that express CLDN18.2 and have not responded to standard therapies.
What could go wrong
This is a very early, small study (18 people) focused on safety and dosing. CAR T cell therapies can cause serious side effects, and it is unknown if this approach will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Willing to sign the Informed Consent Form (ICF) and comply with predefined visits and related procedures; * Age 18 to 75, male or female; * Cytology or histology confirmed advanced malignant solid tumors, with moderate to high expression of CLDN18.2; * Locally advanced or metastatic solid tumors that are failed of, or refractory to, or contraindicated for standard of care; * ECOG PS 0-1; * The life expectency ≥ 3 months; * Has sufficient organ and bone marrow function. Exclusion Criteria: * Have active central nervous system metastases or infiltration; * Has previously received a bone marrow or organ transplant (including, but not limited to, a liver transplant) or is awaiting a transplant; * History of or concurrent other malignancies (cured cervical carcinoma in situ with no recurrence within at least 2 years prior to screening, non-invasive basal cell or squamous cell carcinoma of the skin, locally advanced prostate cancer treated with radical surgery, or post-radical surgery ductal carcinoma in situ may be eligible for the study). * Infectious disease; * Adverse events caused by prior anti-tumor therapy that have not resolved to grade 1 or baseline, except for alopecia, grade 2 peripheral neuropathy, and stable hypothyroidism with hormone replacement therapy; * Have received live attenuated vaccine within one month before screening, or plan to receive live attenuated vaccine during the study; * Have major surgery (except liver space-occupying biopsy) within one month before screening, or have planned major surgery during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced malignant solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLDN18.2 positive solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital Of Anhui Medical University

    RECRUITING

    Hefei, Anhui, 230022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.